Guerbet SA (FRA:4G8)

Market Cap	112.40M -58.7%
Revenue (ttm)	798.67M -6.2%
Net Income	-108.33M
EPS	-8.59
Shares Out	n/a
PE Ratio	n/a
Forward PE	5.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	8.51
Previous Close	8.69
Day's Range	8.51 - 8.51
52-Week Range	7.74 - 23.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 15, 2026

About Guerbet

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; ...

• Industry: X-Ray Apparatus and Tubes and Related Irradiation Apparatus
• Founded: 1901
• Employees: 2,700
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4G8

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error